Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.

导出 LinkOut

翻译打印收藏纠错

作者： Elin,Aamdal ^[1] ; Else Marit,Inderberg ^[2] ; Espen Basmo,Ellingsen ^[3] ; Wenche,Rasch ^[4] ; Paal Fredrik,Brunsvig ^[2] ; Steinar,Aamdal ^[5] ; Karen-Marie,Heintz ^[6] ; Daniel,Vodák ^[6] ; Sigve,Nakken ^[1] ; Eivind,Hovig ^[1] ; Marta,Nyakas ^[2] ; Tormod Kyrre,Guren ^[6] ; Gustav,Gaudernack ^[5]

作者单位： Department of Oncology, Oslo University Hospital, Oslo, Norway. ^[1] Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ^[2] Department of Oncology, Akershus University Hospital, Lørenskog, Norway. ^[3] Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. ^[4] Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ^[5] Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway. ^[6] Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ^[7] Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway. ^[8]

关键词 ipilimumab melanoma peptide vaccine immunotherapy phase I/IIa studies telomerase (hTERT)